help button home button Am J Pathol ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tabibzadeh, S. S.
Right arrow Articles by Sehgal, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tabibzadeh, S. S.
Right arrow Articles by Sehgal, P. B.

American Journal of Pathology, Vol 135, 427-433, Copyright © 1989 by American Society for Investigative Pathology

REGULAR ARTICLES

Interleukin-6 immunoreactivity in human tumors

SS Tabibzadeh, D Poubouridis, LT May and PB Sehgal
Department of Pathology, City Hospital Center, Elmhurst, NY 11373.

The cytokine, interleukin-6 (IL-6), has emerged as a likely mediator of many of the systemic alterations observed in patients with cancer (fever, increased erythrocyte sedimentation rate, and alterations in plasma protein composition) and may also mediate local effects such as alteration in proliferation of tumor cells, increased tumor cell motility, and decreased intercellular adhesions between tumor cells. The distribution of IL-6 immunoreactivity in different human tumors was studied. IL-6 immunoreactivity was detected by the avidin-biotin- complex (ABC) procedure using a polyclonal rabbit antiserum raised against an E coli-derived human IL-6 (rIL-6). Preimmune rabbit serum used as a control did not yield specific staining and preadsorption of the IL-6 antiserum with rIL-6 abolished specific staining. Strong-to- moderate IL-6 immunoreactivity was observed in the neoplastic elements present in primary squamous cell carcinomas, in adenocarcinomas of mammary, colonic, ovarian, and endometrial origin, in various adenocarcinomas metastatic to lymph nodes, and in soft tissue tumors including leiomyosarcoma and neurofibrosarcoma. Weak-to-moderate IL-6 immunostaining was observed in Hodgkin's and non-Hodgkin's lymphomas. This study demonstrates that most human tumors stain positively for IL- 6, adding weight to the hypothesis that IL-6 is a key cytokine that participates in the host-tumor interaction.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. Rancourt, A. Piche, J. Gomez-Navarro, M. Wang, R. D. Alvarez, G. P. Siegal, G. M. Fuller, S. A. Jones, and D. T. Curiel
Interleukin-6 Modulated Conditionally Replicative Adenovirus as an Antitumor/Cytotoxic Agent for Cancer Therapy
Clin. Cancer Res., January 1, 1999; 5(1): 43 - 50.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American Society for Investigative Pathology.